Spero Therapeutics (NASDAQ:SPRO) Downgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Spero Therapeutics (NASDAQ:SPRO) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

Other equities analysts have also recently issued reports about the company. TheStreet cut Tilly’s from a b- rating to a c+ rating in a research report on Tuesday, June 25th. Cantor Fitzgerald restated a buy rating and set a $27.00 target price on shares of Spero Therapeutics in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $19.50.

Spero Therapeutics stock opened at $9.92 on Wednesday. Spero Therapeutics has a 52 week low of $5.52 and a 52 week high of $14.48. The business’s 50-day simple moving average is $11.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 17.48 and a current ratio of 17.48. The stock has a market capitalization of $178.92 million, a PE ratio of -3.82 and a beta of 2.10.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Thursday, May 9th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.49. Spero Therapeutics had a negative return on equity of 34.34% and a negative net margin of 342.70%. The business had revenue of $7.72 million during the quarter, compared to analysts’ expectations of $1.25 million. Equities research analysts predict that Spero Therapeutics will post -3.06 EPS for the current year.

A number of hedge funds have recently modified their holdings of SPRO. Marshall Wace LLP bought a new stake in Spero Therapeutics during the first quarter worth about $39,000. Rhumbline Advisers bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $62,000. PNC Financial Services Group Inc. lifted its stake in shares of Spero Therapeutics by 58.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 15,800 shares of the company’s stock valued at $98,000 after acquiring an additional 5,800 shares during the last quarter. IHT Wealth Management LLC bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at about $115,000. Finally, Virtu Financial LLC bought a new stake in shares of Spero Therapeutics in the 1st quarter valued at about $134,000. 46.70% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Story: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.